Official facilitator of

the main

Olaparib slow the progression of pancreatic cancer with BRCA mutation

June 3, 2019 17:26

According to the study of pancreatic phase 3, patients with metastatic pancreatic cancer gene BRCA mutation notice slowing disease progression due olaparibu (Lynparza company AstraZeneca).

For information on how to carry out the treatment of pancreatic cancer in Israel, the best specialists of the country, leave a request and we will contact you shortly.

Olaparib enzymes is an inhibitor of poly (ADP-ribose) polymerase (PARP), which has already been approved for use in ovarian cancer and breast cancer. The results were presented at the annual meeting of the American Society of Clinical Oncology.

Hedy L. Kindler, MD, and colleagues conducted a study on patients undergoing chemotherapy, one of which gave olaparib, and another - a placebo.

Researchers have found that patients treated with olaparib median progression-free survival was 7.4 months in comparison to 3.8 months with placebo, corresponding to a decrease of risk of disease progression by 47%.

At a press conference Kindler said that after platinum-based chemotherapy olaparib should become the new standard treatment for patients with metastatic pancreatic cancer. She added that the study opens the door to a new era of personalized treatment of this cancer. This is the first time that a drug target stops the growth of metastatic pancreatic cancer in a human with a mutation BRCA.

Kindler said that currently the standard treatment for metastatic pancreatic cancer is chemotherapy with gemcitabine and nab-paclitaxel. The overall survival rate is only 8-12 months.

The goal of maintenance treatment in this subgroup of patients - to delay the progression of the disease after chemotherapy without deterioration of quality of life related to health.

In the study, phase 2, which showed that olaparib has antitumor activity when pre-treatment of pancreatic cancer, the researchers examined patient data from 12 countries.

Serious adverse events were reported in 24% of patients taking olaparib, and 15% of patients receiving placebo. Adverse events leading to discontinuation of the drug, observed at 6% and 2% of patients, respectively.

"This study defines a new treatment option for some people with pancreatic cancer - says Eileen O'Reilly, MD, an oncologist -. We expect the application to the Office of the US Food and Drug Administration to expand the approved indications for olapariba inclusion of people with pancreatic cancer who have a genetic mutation BRCA ».

However, the study has not yet given an answer to the question of how to treat patients with the BRCA somatic mutations, as they were not included in the study.



The form Submitting the this by you agree to the privacy policy


No comments yet

new comment


definitely (will not be published)